Advertisement

Hypnotika und Sedativa

  • Martin J. Lohse
  • Bruno Müller-Oerlinghausen

Zusammenfassung

Auffälligste Entwicklung bei den Schlafmitteln ist der seit über 20 Jahren zu beobachtende starke Verordnungsrückgang um über 75%. Die Rückgänge betrugen im vergangenen Jahr bei den Benzodiazepinen 11%. Seit 2010 gehen auch die Verordnungen der Benzodiazepinagonisten Zolpidem und Zopiclon zurück, in 2013 um 5%. Dagegen haben die Verordnungen von Melatonin wiederum um über 10% zugenommen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. American Academy of Sleep Medicine (2005): The international classification of sleep disorders. 2nd EdGoogle Scholar
  2. Anonym (2007): Zolpidem (Stilnox u. a.): Schlafwandeln, „Schlafessen“ und „Schlaffahren“. Arzneitelegramm 38: 31–32Google Scholar
  3. Becker HF, Mayer G, Penzel T (2004): Schlafstörungen und schlafbezogene Atmungsstörungen. Internist 45: 57–81PubMedGoogle Scholar
  4. Bjorvatn B, Fiske E, Pallesen S (2011): A self-help book is better than sleep hygiene advice for insomnia: a randomized controlled comparative study. Scand J Psychol. 52: 580–585PubMedCrossRefGoogle Scholar
  5. Black JE, Brooks SN, Nishino S (2004): Narcolepsy and syndromes of primary excessive daytime somnolence. Semin Neurol 24: 271–282PubMedCrossRefGoogle Scholar
  6. Brzezinski A, Vangel MG, Wurtman RJ, Norrie G, Zhdanova I, Ben-Shushan A, Ford I (2005): Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev 9: 41–50PubMedCrossRefGoogle Scholar
  7. Buscemi N, Vandermeer B, Hooton N, Pandya R, Tjosvold L, Hartling L, Baker G, Klassen TP, Vohra S (2005): The efficacy and safety of exogenous melatonin for primary sleep disorders. A meta-analysis. J Gen Intern Med 20: 1151–1158PubMedCentralPubMedCrossRefGoogle Scholar
  8. Cimolai N (2007): Zopiclone: is it a pharmacologic agent for abuse? Can Fam Physician 53: 2124–2129PubMedCentralPubMedGoogle Scholar
  9. Crestani F, Martin JR, Möhler H, Rudolph U (2000): Mechanism of action of the hypnotic zolpidem in vivo. Br J Pharmacol 131: 1251–1254PubMedCentralPubMedCrossRefGoogle Scholar
  10. Deutsche Gesellschaft für Neurologie (DGN) (2012a): S1-Leitlinie Restless-Legs-Syndrom (RLS) und Periodic Limb Movement Disorder (PLMD) http://www.awmf.org/leitlinien/detail/ll/030-081.html
  11. Deutsche Gesellschaft für Neurologie (DGN) (2012b): S1-Leitlinie Insomnie http://www.awmf.org/leitlinien/detail/ll/030-045.html
  12. Deutsche Gesellschaft für Neurologie (DGN) (2012c): S1-Leitlinie Narkolepsie http://www.awmf.org/leitlinien/detail/ll/030-056.html
  13. Deutsche Gesellschaft für Schlafforschung und Schlafmedizin (DGSM) (2009): S3-Leitlinie Nicht erholsamer Schlaf/Schlafstörungen. Somnologie 13: 4–160. Internet: www.awmf.org/leitlinien/detail/ll/063-001.html
  14. Dündar Y, Dodd S, Strobl J, Boland A, Dickson R, Walley T (2004): Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: a systematic review and meta-analysis. Hum Psychopharmacol. 19: 305–322PubMedCrossRefGoogle Scholar
  15. European Medicines Agency (2007): Circadin. Europäischer öffentlicher Beurteilungsbericht (EPAR). Internet: www.emea.europa.eu/humandocs/PDFs/EPAR/circadin/H-695-en6.pdf
  16. European Medicines Agency (2009/2011): Guideline on medicinal products for the treatment of insomnia. EMA/CHMP/16274/2009. Internet: www.ema.europa.eu/ema/pages/includes/document/open_document.jsp?webContentId=WC500102351
  17. Farkas RH, Unger EF, Temple R (2013): Zolpidem and driving impairment – identifying persons at risk. N Engl J Med 369: 689–691PubMedCrossRefGoogle Scholar
  18. Garcia-Borreguero D, Odin P, Schwarz C (2004): Restless legs syndrome: an overview of the current understanding and management. Acta Neurol Scand 109: 303–317PubMedGoogle Scholar
  19. Glass JR, Sproule BA, Herrmann N, Streiner D, Busto UE (2003): Acute pharmacological effects of temazepam, diphenhydramine, and valerian in healthy elderly subjects. J Clin Psychopharmacol 23: 260–268PubMedGoogle Scholar
  20. Glass J, Lanctot KL, Herrmann N, Sproule BA, Busto UE (2005): Sedative hypnotics in older people with insomnia : meta-analysis of risks and benefits. Br Med J 331: 116–9CrossRefGoogle Scholar
  21. Hajak G, Müller WE, Wittchen HU, Pittrow D, Kirch W (2003): Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data. Addiction 98: 1371–1378PubMedCrossRefGoogle Scholar
  22. Happe S (2003): Excessive daytime sleepiness and sleep disturbances in patients with neurological diseases: epidemiology and management. Drugs 63: 2725–2737PubMedCrossRefGoogle Scholar
  23. Haupt M, Cruz-Jentoft A, Jeste D (2006): Mortality in elderly dementia patients treated with risperidone. J Clin Psychopharmacol 26: 566–570PubMedGoogle Scholar
  24. Herxheimer A (2005): Jet lag. Clin Evid 13: 2178–2183PubMedGoogle Scholar
  25. Herxheimer A, Petrie KJ (2002): Melatonin for the prevention and treatment of jet lag. Cochrane Database Syst Rev. 2002; (2): CD001520PubMedGoogle Scholar
  26. Hoffmann F, Glaeske G (2014): Benzodiazepinhypnotika, Zolpidem und Zopiclon auf Privatrezept. Nervenarzt (im Druck)Google Scholar
  27. Huedo-Medina TB, Kirsch I, Middlemass J, Klonizakis M, Siriwardena AN (2012): Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the Food and Drug Administration. BMJ Dec 17;345: e834–3Google Scholar
  28. Jacobs GD, Pace-Schott EF, Stickgold R, Otto MW (2004): Cognitive behavior therapy and pharmacotherapy for insomnia: a randomized controlled trial and direct comparison. Arch Intern Med 164: 1888–1896PubMedCrossRefGoogle Scholar
  29. Klotz U (1995): Benzodiazepin-Hypnotika; Pharmakokinetik. In: Riederer P, Laux G, Pöldinger W (Hrsg): Neuropsychopharmaka, Bd 2. Springer-Verlag, Wien, S. 135–139Google Scholar
  30. Kripke DF, Langer RD, Kline LE (2012): Hypnotics' association with mortality or cancer: a matched cohort study. BMJ Open. 2012 Feb 27;2(1):e00085–0Google Scholar
  31. Lader M (1987): Clinical Pharmacology of Benzodiazepines. Ann Rev Med 38: 19–28PubMedCrossRefGoogle Scholar
  32. Lancee J, van den Bout J, van Straten A, Spoormaker VI (2012): Internet-delivered or mailed self-help treatment for insomnia?: a randomized waiting-list controlled trial. Behav Res Ther 50: 22–29PubMedCrossRefGoogle Scholar
  33. Lemoine P, Nir T, Laudon M, Zisapel N (2007): Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects. J Sleep Res 16: 372–380PubMedCrossRefGoogle Scholar
  34. Mattila T, Stoyanova V, Elferink A, Gispen-de Wied C, de Boer A, Wohlfarth T (2011): Insomnia medication: do published studies reflect the complete picture of efficacy and safety? Eur Neuropsychopharmacol 21: 500–507PubMedCrossRefGoogle Scholar
  35. Ministry of Health and Social Policy (2009): Clinical practice guidelines for the management of patients with insomnia in primary care. Madrid. Internet: www.guiasalud.es/egpc/traduccion/ingles/insomnio/completa/Google Scholar
  36. Morgan K, Dixon S, Mathers N, Thompson J, Tomeny M (2003): Psychological treatment for insomnia in the management of long-term hypnotic drug use: a pragmatic randomised controlled trial. Br J Gen Pract 53: 923–928PubMedCentralPubMedGoogle Scholar
  37. Morin CM, Benca R (2012): Chronic insomnia. Lancet 379: 1129–1141PubMedCrossRefGoogle Scholar
  38. Morin CM, Bootzin RR, Buysse DJ, Edinger JD, Espie CA, Lichstein KL (2006): Psychological and behavioral treatment of insomnia. Sleep 29: 1398–1414PubMedGoogle Scholar
  39. National Institute for Clinical Excellence, Technology appraisal guidance 77 (2004): Zaleplon, zolpidem and zopiclone for the short term management of insomnia. Internet: www.nice. org.uk/TA077Google Scholar
  40. National Institutes of Health state of the science conference statement (2005): Manifestations and management of chronic insomnia in adults. Sleep 28: 1049–1057Google Scholar
  41. Ohayon MM (2002): Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev 6: 97–111PubMedCrossRefGoogle Scholar
  42. Perlis ML, McCall WV, Krystal AD, Walsh JK (2004): Long-term, non-nightly administration of zolpidem in the treatment of patients with primary insomnia. J Clin Psychiatry 65: 1128–1137PubMedCrossRefGoogle Scholar
  43. Randall S, Roehrs TA, Roth T (2012): Efficacy of eight months of nightly zolpidem: a prospective placebo-controlled study. Sleep. 35: 1551–1557PubMedCentralPubMedGoogle Scholar
  44. Riemann D, Hajak G (2009a): Insomnien. I. Ätiologie, Pathophysiologie und Diagnostik. Nervenarzt 80: 1060–1069Google Scholar
  45. Riemann D, Hajak G (2009b): Insomnien. II. Pharmakologische und psychotherapeutische Behandlungsmöglichkeiten. Nervenarzt 80: 1327–1340Google Scholar
  46. Roehrs TA, Randall S, Harris E, Maan R, Roth T (2012): Twelve months of nightly zolpidem does not lead to rebound insomnia or withdrawal symptoms: a prospective placebo-controlled study. J Psychopharmacol. 26: 1088–1095PubMedCentralPubMedCrossRefGoogle Scholar
  47. Sack RL (2010): Clinical practice. Jet lag.N Engl J Med 362: 440–447PubMedCrossRefGoogle Scholar
  48. Sarris J, Byrne GJ (2011): A systematic review of insomnia and complementary medicine. Sleep Med Rev 15: 99–106PubMedCrossRefGoogle Scholar
  49. Sateia MJ, Nowell PD (2004): Insomnia. Lancet. 364: 1959–73PubMedCrossRefGoogle Scholar
  50. Schenck CH, Mahowald MW, Sack RL (2003): Assessment and management of insomnia. JAMA 289: 2475–2479PubMedCrossRefGoogle Scholar
  51. Schapira AH (2004): Restless legs syndrome: an update on treatment options. Drugs 64: 149–158PubMedCrossRefGoogle Scholar
  52. Schutte-Rodin S, Broch L, Buysse D, Dorsey C, Sateia M (2008): Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med. 4: 487–504PubMedCentralPubMedGoogle Scholar
  53. Shen J, Chung SA, Kayumov L, Moller H, Hossain N, Wang X et al (2006): Polysomnographic and symptomatological analyses of major depressive disorder patients treated with mirtazapine. Can J Psychiatry 51: 27–34PubMedGoogle Scholar
  54. Walsh JK, Roth T, Randazzo A, Erman M, Jamieson A, Scharf M, Schweitzer PK, Ware JC (2000): Eight weeks of non-nightly use of zolpidem for primary insomnia. Sleep 23:1087–1096PubMedGoogle Scholar
  55. Weich S, Pearce HL, Croft P, Singh S, Crome I, Bashford J, Frisher M (2014): Effect of anxiolytic and hypnotic drug prescriptions on mortality hazards: retrospective cohort study. BMJ 2014 Mar 19; 348: g1996. doi: 10.1136/bmj.g1996PubMedCentralPubMedGoogle Scholar
  56. Wiegand MH (2003): Arzneimittelbehandlung von Schlafstörungen im Alter. Internist 44: 1187–1192PubMedGoogle Scholar
  57. Wilson SJ, Nutt DJ, Alford C, Argyropoulos SV, Baldwin DS, Bateson AN, Britton TC, Crowe C, Dijk DJ, Espie CA, Gringras P, Hajak G, Idzikowski C, Krystal AD, Nash JR, Selsick H, Sharpley AL, Wade AG (2010): British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. J Psychopharmacol 24: 1577–1601PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Martin J. Lohse
    • 1
  • Bruno Müller-Oerlinghausen
    • 2
  1. 1.Institut für Pharmakologie und ToxikologieUniversität WürzburgWürzburg
  2. 2.Berlin

Personalised recommendations